NCT03276598View on ClinicalTrials.gov

A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

233

Participants

Timeline

Start Date

November 25, 1999

Primary Completion Date

April 1, 2004

Study Completion Date

April 1, 2004

Conditions
HypertensionPharmacogenetics
Interventions
DRUG

Amlodipine

Treatment for four weeks. Dose: 5 mg o.d.

DRUG

Bisoprolol

Treatment for four weeks. Dose: 5 mg o.d.

DRUG

Hydrochlorothiazide

Treatment for four weeks. Dose: 25 mg o.d.

DRUG

Losartan

Treatment for four weeks. Dose: 50 mg o.d.

DRUG

Placebo

Treatment for four weeks. Dose: 1 tablet per day.

Trial Locations (1)

Unknown

Helsinki University Central Hospital, Helsinki

All Listed Sponsors
lead

Helsinki University Central Hospital

OTHER

NCT03276598 - A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension | Biotech Hunter | Biotech Hunter